Search

Your search keyword '"Baertsch, Marc‐Andrea"' showing total 12 results
Start Over Author "Baertsch, Marc‐Andrea" Search Limiters Available in Library Collection
12 results on '"Baertsch, Marc‐Andrea"'

2. Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

Author

Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Schlenzka, Jana, Salwender, Hans J., Munder, Markus, Gerecke, Christian, Dührsen, Ulrich, Brossart, Peter, Neben, Kai, Hillengass, Jens, Raab, Marc S., Merz, Maximilian, Baertsch, Marc-Andrea, Jauch, Anna, Hose, Dirk, Martin, Hans, Lindemann, Hans-Walter, Blau, Igor W., Scheid, Christof, Weisel, Katja C., Goldschmidt, Hartmut, and for the German-speaking Myeloma Multicenter Group (GMMG)

Published
2019
Full Text
View/download PDF

4. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma

Author

Baertsch, Marc-Andrea, primary, Fougereau, Mathilde, additional, Hielscher, Thomas, additional, Sauer, Sandra, additional, Breitkreutz, Iris, additional, Jordan, Karin, additional, Müller-Tidow, Carsten, additional, Goldschmidt, Hartmut, additional, Raab, Marc-Steffen, additional, Hillengass, Jens, additional, and Giesen, Nicola, additional

Published
2021
Full Text
View/download PDF

5. Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

Author

Kriegsmann, Katharina, primary, Baertsch, Marc-Andrea, additional, Awwad, Mohamed H. S., additional, Merz, Maximilian, additional, Hose, Dirk, additional, Seckinger, Anja, additional, Jauch, Anna, additional, Becker, Natalia, additional, Benner, Axel, additional, Raab, Marc S., additional, Hillengass, Jens, additional, Bertsch, Uta, additional, Dürig, Jan, additional, Salwender, Hans Jürgen, additional, Hänel, Mathias, additional, Fenk, Roland, additional, Munder, Markus, additional, Weisel, Katja, additional, Müller-Tidow, Carsten, additional, Goldschmidt, Hartmut, additional, and Hundemer, Michael, additional

Published
2019
Full Text
View/download PDF

6. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.

Author

Baertsch, Marc-Andrea, Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Munder, Markus, Fuhrmann, Stephan, Dührsen, Ulrich, Brossart, Peter, Neben, Kai, Schlenzka, Jana, Kunz, Christina, Raab, Marc S., Hillengaß, Jens, Jauch, Anna, Seckinger, Anja, Hose, Dirk, Luntz, Steffen, Sonneveld, Pieter, and Lokhorst, Henk

Subjects
BORTEZOMIB, ANTINEOPLASTIC agents, DRUG efficacy, MULTIPLE myeloma treatment, STEM cell transplantation, CANCER chemotherapy, CLINICAL trials
Abstract

Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1–21 of 28 day cycles) followed by 10–15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (p = 0.57). Progression-free survival (PFS; HR = 0.83, p = 0.18) and overall survival (OS; HR = 0.70, p = 0.15) did not differ significantly with LEN vs. BTZ MT. Patients with

Published
2021
Full Text
View/download PDF

7. Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites

Author

Leber, Mathias Felix, primary, Baertsch, Marc-Andrea, additional, Anker, Sophie Caroline, additional, Henkel, Luisa, additional, Singh, Hans Martin, additional, Bossow, Sascha, additional, Engeland, Christine E., additional, Barkley, Russell, additional, Hoyler, Birgit, additional, Albert, Jessica, additional, Springfeld, Christoph, additional, Jäger, Dirk, additional, von Kalle, Christof, additional, and Ungerechts, Guy, additional

Published
2018
Full Text
View/download PDF

9. Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial

Author

Wuchter, Patrick, primary, Bertsch, Uta, additional, Salwender, Hans-Juergen, additional, Munder, Markus, additional, Haenel, Mathias, additional, Benner, Axel, additional, Becker, Natalia, additional, Fenk, Roland, additional, Duerig, Jan, additional, Blau, Igor Wolfgang, additional, Lisenko, Katharina, additional, Hillengass, Jens, additional, Raab, Marc S., additional, Baertsch, Marc Andrea, additional, Seidel-Glaetzer, Andrea, additional, Ho, Anthony D, additional, Graeven, Ullrich, additional, Scheid, Christof, additional, Weisel, Katja, additional, and Goldschmidt, Hartmut, additional

Published
2016
Full Text
View/download PDF

10. Spatial Dissection of the Bone Marrow Microenvironment in Multiple Myeloma By High Dimensional Multiplex Tissue Imaging

Author

Baertsch, Marc-Andrea, Brobeil, Alexander, Hickey, John, Haist, Maximilian, Poos, Alexandra Maria, Lu, Guolan, Kuswanto, Wilson, Schuerch, Christian, Voehringer, Harald, Huber, Wolfgang, Mechtersheimer, Gunhild, Mueller-Tidow, Carsten, Schirmacher, Peter, Weisel, Katja, Fenk, Roland, Goldschmidt, Hartmut, Goltsev, Yury, Raab, Marc S., Weinhold, Niels, and Nolan, Garry P.

Abstract

Introduction

Published
2023
Full Text
View/download PDF

11. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

Author

Baertsch, Marc-Andrea, primary, Schlenzka, Jana, additional, Mai, Elias K., additional, Merz, Maximilian, additional, Hillengaß, Jens, additional, Raab, Marc S., additional, Hose, Dirk, additional, Wuchter, Patrick, additional, Ho, Anthony D., additional, Jauch, Anna, additional, Hielscher, Thomas, additional, Kunz, Christina, additional, Luntz, Steffen, additional, Klein, Stefan, additional, Schmidt-Wolf, Ingo G. H., additional, Goerner, Martin, additional, Schmidt-Hieber, Martin, additional, Reimer, Peter, additional, Graeven, Ullrich, additional, Fenk, Roland, additional, Salwender, Hans, additional, Scheid, Christof, additional, Nogai, Axel, additional, Haenel, Mathias, additional, Lindemann, Hans W., additional, Martin, Hans, additional, Noppeney, Richard, additional, Weisel, Katja, additional, and Goldschmidt, Hartmut, additional

Published
2016
Full Text
View/download PDF

12. Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.

Author

Baertsch, Marc-Andrea, Kriegsmann, Katharina, Pavel, Petra, Bruckner, Thomas, Hundemer, Michael, Kriegsmann, Mark, Ho, Anthony D., Goldschmidt, Hartmut, and Wuchter, Patrick

Subjects
*BLOOD platelets, *BLOOD transfusion, *LEUCOCYTES, *BLOOD cell count, *BONE marrow
Abstract

Background: A low platelet count before mobilization has recurrently been identified as risk factor for poor mobilization. Methods: To determine the relevance of this finding for peripheral blood stem cell (PBSC) mobilization, including pre-emptive or rescue plerixafor in the case of poor mobilization, we retrospectively analyzed all patients undergoing PBSC collection at our institution between January 2014 and December 2015 (n = 380). Results: In total, 99% of the patients (377/380) successfully collected a minimum of 2 × 106 CD34+ cells/kg body weight sufficient for a single transplant. Rescue or pre-emptive plerixafor was administered to 11% of the patients (42/380). No correlations between the platelet count before mobilization and the number of peripheral blood CD34+ cells or the CD34+ cell collection result were detected in the entire population or the subgroups according to diagnosis (newly diagnosed multiple myeloma, relapsed multiple myeloma, lymphoma, amyloid light-chain amyloidosis, sarcoma, or germ cell tumor). However, patients requiring pre-emptive or rescue plerixafor had a significantly lower platelet count before mobilization (217/nl vs. 245/nl; p = 0.004). Conclusion: With the current state of the art PBSC mobilization strategies, the platelet count before mobilization was not associated with the CD34+ cell collection result but was associated with the need for pre-emptive or rescue application of plerixafor. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results